Cancer Research Targets  Genetics and Biology of Brain Cancer
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

[Cancer Research 53, 4613-4618, October 1, 1993]
© 1993 American Association for Cancer Research

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Traganos, F.
Right arrow Articles by Darzynkiewicz, Z.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Traganos, F.
Right arrow Articles by Darzynkiewicz, Z.

Caffeine Prevents Apoptosis and Cell Cycle Effects Induced by Camptothecin or Topotecan in HL-60 Cells1

Frank Traganos2, Jan Kapuscinski, Jianping Gong, Barbara Ardelt, Robert J. Darzynkiewicz and Zbigniew Darzynkiewicz

The Cancer Research Institute at New York Medical College, Valhalla, New York 10595

2 To whom requests for reprints should be addressed, at The Cancer Research Institute, New York Medical College, 100 Grasslands Road, Elmsford, NY 10523.

Caffeine (3,7-dihydro-1,3,7,-trimethyl-1H-purine-6,6-dione; CAF) is known to potentiate the cytotoxic effects of DNA damaging agents such as ionizing radiation and alkylating agents. In contrast, however, the cytotoxic and cytostatic activity of aromatic, DNA-intercalating, DNA topoisomerase II inhibitors such as Adriamycin, ellipticine, or mitoxantrone are diminished in the presence of CAF. To resolve whether the protective effect of CAF is associated with a particular mechanism of drug interaction (e.g., intercalation into DNA, inhibition of DNA topoisomerase II), or the aromatic nature of the drug structure, per se, we have presently studied the effects of CAF on the cytostatic and cytotoxic action of camptothecin (CAM) and its less toxic but more water soluble derivative topotecan (TPT) on HL-60 human myelogenous leukemia cells: both drugs have aromatic structures but are nonintercalating inhibitors of DNA topoisomerase I. By using spectroscopy and titration microcalorimetry, we have also studied the direct interaction between CAF and TPT in solution. Low (20 nM) concentrations of CAM or TPT perturbed progression of HL-60 cells through S-phase, whereas higher concentrations (0.15 µM) of these drugs induced apoptosis; both effects were easily demonstrable after 4 h of treatment. When added simultaneously with CAM or TPT, CAF prevented both effects. The protective effect of CAF was concentration dependent and evident within the concentration range of 1–5 mM; nearly total protection was seen at a CAF concentration of 5 mM. The bathochromic and hypochromic shift in the absorption spectrum of the water soluble compound TPT upon addition of CAF indicated that CAF and TPT interact (stack) in a fashion similar to that previously observed for CAF and DNA intercalators. Microcalorimetric measurements of TPT titration with CAF indicate an exothermic reaction between these compounds (the enthalpy change was {Delta} = –4.2 kcal/mol), which is consistent with a stacking model of CAF-TPT interaction. Thus, the ability of CAF to protect HL-60 cells against the cell kinetic effects of CAM or TPT, as in the case of DNA intercalating topoisomerase II inhibitors, is most likely due to formation of complexes between CAF and these aromatic molecules, which result in reducing the effective concentration of the free form of these drugs available to the cells.

1 This work was supported by USPHS Grant CA 28704, and grants from the Cancer Research Foundation of America and the Carl Inserra Fund. J. G., on leave from the Department of Surgery, Tongji Hospital, Wuhan, China, is supported by the "This Close" Fellowship from the This Close for Cancer Research Foundation. R. J. D., a graduate student of the University of California at Berkeley, worked as a volunteer during summer vacation.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Received 4/22/93. Accepted 7/27/93.




This article has been cited by other articles:


Home page
Molecular Cancer TherapeuticsHome page
H. Zhu, M. Huang, F. Yang, Y. Chen, Z.-H. Miao, X.-H. Qian, Y.-F. Xu, Y.-X. Qin, H.-B. Luo, X. Shen, et al.
R16, a novel amonafide analogue, induces apoptosis and G2-M arrest via poisoning topoisomerase II
Mol. Cancer Ther., February 1, 2007; 6(2): 484 - 495.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
A. Hemminki, A. Kanerva, B. Liu, M. Wang, R. D. Alvarez, G. P. Siegal, and D. T. Curiel
Modulation of Coxsackie-Adenovirus Receptor Expression for Increased Adenoviral Transgene Expression
Cancer Res., February 15, 2003; 63(4): 847 - 853.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
R. J. Sleiman and B. W. Stewart
Early Caspase Activation in Leukemic Cells Subject to Etoposide-induced G2-M Arrest: Evidence of Commitment to Apoptosis Rather Than Mitotic Cell Death
Clin. Cancer Res., September 1, 2000; 6(9): 3756 - 3765.
[Abstract] [Full Text]


Home page
Cancer Res.Home page
M. Suganuma, T. Kawabe, H. Hori, T. Funabiki, and T. Okamoto
Sensitization of Cancer Cells to DNA Damage-induced Cell Death by Specific Cell Cycle G2 Checkpoint Abrogation
Cancer Res., December 1, 1999; 59(23): 5887 - 5891.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 1993 by the American Association for Cancer Research.